research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
The medullary collecting duct is the main site of ANP regulation of sodium excretion. ANP effects sodium channels at both the apical and basolateral sides. ANP inhibits ENaC on the apical side and the sodium potassium ATPase pump on the basolateral side in a cGMP PKG dependent manner resulting in less sodium re-absorption and more sodium excretion. ANP increases glomerular filtration rate and glomerular permeability. ANP directly dilates the afferent arteriole and counteracts the norepinephrine induced vasoconstriction of the afferent arteriole. Some studies suggest that ANP also constricts the efferent arteriole, but this is not a unanimous finding. ANP inhibits the effect of Angiotensin II on the mesangial cells, thereby relaxing them. ANP increases the radius and number of glomerular pores, thereby increasing glomerular permeability and resulting in greater filter load of sodium and water. Increases blood flow through the vasa recta, which will wash the solutes (sodium chloride (NaCl), and urea) out of the medullary interstitium. The lower osmolarity of the medullary interstitium leads to less reabsorption of tubular fluid and increased excretion. Decreases sodium reabsorption at least in the thick ascending limb (interaction with NKCC2) and cortical collecting duct of the nephron via guanosine 3',5'-cyclic monophosphate (cGMP) dependent phosphorylation of ENaC. It inhibits renin secretion, thereby inhibiting the production of angiotensin and aldosterone. It inhibits the renal sympathetic nervous system.
=== Medical === Hydrocodone/paracetamol is a fixed-dose combination consisting of the opioid hydrocodone and the non-opioid analgesic paracetamol. It is indicated for relief of moderate to severe pain of acute, chronic, or postoperative types. Hydrocodone/paracetamol comes in oral solution and tablet formulations; however strength of each component may vary. In October 2014, the Drug Enforcement Administration rescheduled hydrocodone combination drugs from schedule III, to schedule II due to its risk for misuse, abuse, and diversions.
In 1996, he voted for the Defense of Marriage Act, which prohibited the federal government from recognizing same-sex marriages, thereby barring people in such marriages from equal protection under federal law and allowing states to do the same. In 2015, the act was ruled unconstitutional in Obergefell v. Hodges. Biden was critical of Independent Counsel Ken Starr during the 1990s Whitewater controversy and Clinton–Lewinsky scandal investigations, saying "it's going to be a cold day in hell" before another independent counsel would be granted similar powers. He voted to acquit during the impeachment of Bill Clinton. During the 2000s, Biden sponsored bankruptcy legislation sought by credit card issuers (such as MBNA, one of Delaware's largest companies). Bill Clinton vetoed the bill in 2000, but it passed in 2005 as the Bankruptcy Abuse Prevention and Consumer Protection Act, with Biden being one of only 18 Democrats to vote for it, while leading Democrats and consumer rights organizations opposed it. As a senator, Biden strongly supported increased Amtrak funding and rail security.
Sources: en.wikipedia.org
In October 2023, the EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023. In December 2023, the company acquired Seagen, a pioneer of antibody–drug conjugates for the treatment of cancer, for $43 billion. In December 2023, the EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups. In January 2024, omnichannel strategies were being used to provide tailored healthcare solutions for patients and professionals. In February 2024, Saama and Pfizer reached an expanded multi-year agreement to integrate AI-driven solutions across Pfizer's R&D portfolio, building on their 2020 partnership. Initially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform — developed during Pfizer's COVID-19 vaccine trials — the partnership as of 2024 scales to streamline data review and accelerate regulatory submissions across global studies. The expanded collaboration introduces Saama's Biometrics Research and Analysis Information Network, enabling faster statistical programming, biostatistics workflows, and submission-ready outputs. In February 2024, Pfizer reported durable second-season efficacy for RSV vaccine. In June 2024, Pfizer announced a collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.
=== Initiatives === Santosh Lad was appointed state representative to oversee the rescue operation in the worst flooded area of Uttarakhand, accompanied by a team headed by Hemanth Nimbalkar, Kari Gowda, and Naveen Raj Singh. After over ten days of rescue operations, the team was able to rescue everyone except 14 people for whom an extensive search was carried out.
Born Mary Morse Baker on a farm in Bow, New Hampshire, Eddy was the youngest of six children in a family of Protestant Congregationalists. Her father, Mark Baker, was a deeply religious man, although, according to one account, "Christianity to him was warfare against sin, not a religion of human brotherhood." In common with most women at the time Eddy was given little formal education, but she said she had read widely at home. From childhood she lived with protracted ill health, complaining of chronic indigestion and spinal inflammation, and according to biographers experiencing fainting spells. The literary critic Harold Bloom described her as "a kind of anthology of nineteenth-century nervous ailments". Eddy's first husband died just before her 23rd birthday, six months after they married and three months before their son was born, leaving her penniless; as a result of her poor health she lost custody of the boy when he was four. Her second husband left her after 13 years of marriage; Eddy said that he had promised to become her child's legal guardian, but it is unclear whether he did, and Eddy lost contact with her son until he was in his thirties. (Per the legal doctrine of coverture, women in the United States could not then be their own children's guardians.) Her third husband, Asa Gilbert Eddy, died five years after they married; she believed he had been killed by malicious animal magnetism. Six years later, when she was 67 and apparently in need of loyalty and affection, she legally adopted a 41-year-old homeopath as her second son.
On 16 February, Lula minimized the minister's links with militias in an interview with CNN Brasil, describing the case only as a "photograph":She appeared in a truck there with a militia guy. Honestly, if we take into account people who appear in photographs next to other people, we will not talk to anyone, because I am the guy who takes the most photographs in the world.On 3 March, Lula said in an interview with journalist Reinaldo Azevedo on BandNews FM that he felt "gratitude" toward Daniela because of the support she gave him in the presidential elections. In addition, he stated that the minister would be dismissed from office "if the link with militias goes beyond photos":For now I think it is no more than that. If evidence appears that it is [greater than a photo], she will leave the government.After disagreements with leaders of her own party and requesting disaffiliation from Brazil Union, Daniela was dismissed from the Ministry of Tourism at the party's request and on 14 July was replaced by federal deputy Celso Sabino (UNIÃO/PA). However, on 29 September, Daniela, now affiliated with Republicanos, was appointed vice leader of the government in the Congress.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.